ICON Public Limited Company
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Barry Balfe
- Full Time Employees
- 40,950
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- South County Business Park Dublin Ireland D18 X5R3
- IPO Date
- May 15, 1998
- CIK
- 0001060955
- Website
- iconplc.com
- Similar Companies
- Business
- ICON Public Limited Company (NasdaqGS: ICLR), a leading global clinical research organization (CRO), provides outsourced drug development, commercialization and healthcare intelligence services to pharmaceutical, biotechnology, medical device and government organizations. The company offers a comprehensive portfolio of services including clinical trial management from Phase I through IV; early phase clinical and bioanalytical solutions; cardiac safety solutions encompassing ECG, Holter monitoring, ECHO and MUGA studies; site and patient recruitment with real-world data integration; specialty laboratory services for precision medicine, biomarkers and vaccine testing; market access, pricing and reimbursement consulting; real-world evidence generation; medical imaging; language services; consulting and strategic solutions; decentralized and hybrid trials; and commercial positioning with health economics and outcomes research. ICON operates over 95 locations across approximately 45 countries in the Americas, Europe, Asia-Pacific and Africa, targeting biopharma sponsors and supporting therapeutic areas such as oncology, rare diseases, infectious diseases and cardiovascular. Founded in 1990 and headquartered in Dublin, Ireland, the company employs around 41,000 professionals worldwide. Recent developments include the acquisition of KCR in 2024, enhancing full-service and functional clinical trial capabilities in Europe; the purchase of HumanFirst in 2024, adding cloud-based technology for patient-centered precision measurement; strong gross business wins of $2.97 billion in Q2 2025, up 10.6% sequentially; a share repurchase program expansion to $1 billion authorized; and updated full-year 2025 revenue guidance of $7.85-$8.15 billion with adjusted EPS of $13.00-$14.00.
ICON Q1 2026: Margins Face Questions, But The Long-Term Thesis Holds
Why Icon Stock Crushed it on Wednesday
ICON Public Limited Company (ICLR) Q1 2026 Earnings Call Transcript
ICON Reports First Quarter 2026 Results
ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development
ICON Schedules First Quarter 2026 Earnings Conference Call
Wells Fargo Named as ICON Preferred Mortgage Lender to Support 3D‑Printed Homes
ICON Stock Valuation vs Peers: Is ICLR Cheap Enough?
ICLR Earnings Reset: What the Accounting Probe Changed
The Cooper Companies (COO) Beats Q2 Earnings and Revenue Estimates
ICON Plc: FY25 Shows Reset Before Reacceleration
ICON Public Limited Company (ICLR) Q4 2025 Earnings Call Transcript
Icon Q4 Earnings Call Highlights
Icon PLC (ICLR) Stock Up 4.0% and Still Undervalued -- GF Score: 79/100
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq
ICON expands US early phase research capabilities with new clinic and outpatient centres
Artisan International Value Fund Q1 2026 Portfolio Update
A Look at Icon PLC (ICLR) After 4.7% Decline -- GF Value $241.81 vs Price $118.96
Polen International Growth Q1 2026 Portfolio Activity